1 Title [216/250 characters]

2 "Kankasha" in Kassala: a prospective observational cohort study of the clinical characteristics,

- 3 epidemiology, genetic origin, and chronic impact of the 2018 epidemic of Chikungunya virus
- 4 infection in Kassala, Sudan
- 5 Short title: [66/70characters]
- 6 Understanding the 2018 Chikungunya virus epidemic in Eastern Sudan
- 7
- 8 **Authors**: Hilary Bower^{1*}, Mubarak el Karsany^{2,3*}, Abd Alhadi Adam Hussein⁴, Mubarak Ibrahim
- 9 Idriss⁵, Ma'aaza Abasher AlZain⁶, Mohamed Elamin Ahmed Alfakiyousif², Rehab Mohamed², Iman
- 10 Mahmoud², Omer Albadri,⁷ Suha Abdulaziz Alnour Mahmoud¹⁰, Orwa Ibrahim Abdalla¹⁰, Mawahib
- 11 Eldigail², Nuha Elagib², Ulrike Arnold¹, Bernardo Gutierrez⁸, Oliver G. Pybus⁸, Daniel P. Carter⁹, Steven
- 12 T. Pullan⁹, Shevin T. Jacob¹¹, Tajeldin Mohammedein Abdallah^{4,10#}, Benedict Gannon^{1#}, Tom E.
- 13 Fletcher^{11#}
- 14 * Equal first authors, [#]Equal senior authors
- 15

16 Authors' affiliations

- 17 1. UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health
- 18 England, London, United Kingdom
- 19 2. National Public Health Laboratory, Federal Ministry of Health, Khartoum, Sudan
- 20 3. Karary University, Omdurman, Sudan
- 21 4. University of Kassala, Kassala, Sudan
- 22 5. Laboratory Division, Kassala State Ministry of Health, Kassala, Sudan
- 23 6. Communicable Disease Surveillance & Events Unit, Federal Ministry of Health, Khartoum, Sudan
- 24 7. Health Emergency and Epidemic Control Directorate, Federal Ministry of Health, Khartoum, Sudan
- 25 8. Department of Zoology, University of Oxford, Oxford, United Kingdom
- 26 9. National Infection Service, Public Health England, Porton, United Kingdom
- 27 10. Kassala Teaching Hospital, Kassala, Sudan
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 11. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

2

29 Authors' contributions

- 30 Conceptualisation : TEF, HB, MEK, OGP, BGa, STP
- 31 Data curation : IM, AAAH, HB, BGa
- 32 Formal analysis : HB, BGu, OGP, TEF
- 33 Funding acquisition: HB
- 34 Investigation: MEK, MAZ, MEAA, AAAH, MII, OA, SAAM, OIA, RM, MED, UA, BGu, OGP, DPC, STP, TMA,
- 35 **BGa TEF**
- 36 Methodology: HB, MEK, BGa, TEF,
- 37 Project administration: HB, MEK, TMA, TEF
- 38 Resources : HB, MEK, TEF, AAAH, NEA, BGu, OGP, BGa
- 39 Software : DPC, BGu
- 40 Supervision : HB, MEK, TMA, BGa, TEF
- 41 Validation : not applicable
- 42 Writing – original draft preparation: HB, TEF
- Writing review & editing: HB, MEK, AAAH, MII, MAZ, MEAA, RM, IM, OA, SAAM, OIA, MED, NEA, UA, 43
- 44 BGu, OGP, DPC, STP, STJ, TMA, BGa, TEF
- 45

46 Role of the funding source

- 47 The study was funded by UK aid from the Department of Health and Social Care
- (https://www.gov.uk/government/collections/official-development-assistance-oda--2, Grant No. IS-48
- 49 RRT-1015-001) via the UK Public Health Rapid Support Team Research Programme (Grant No.
- 50 RST3 03). The funder had no role in study design, data collection and analysis, decision to publish or
- 51 preparation of the manuscript.
- 52

Competing interests 53

54 All authors declare no competing interests

- 56 57
- 58

3

59 **Abstract** [300w]

60 Background

The public health impact of Chikungunya virus (CHIKV) is often underestimated. Usually considered a mild condition of short duration, recent outbreaks have reported greater incidence of severe illness, fatality, and longer-term disability. In 2018/19, Eastern Sudan experienced the largest epidemic of CHIKV in Africa to date, affecting an estimated 487,600 people. Known locally as Kankasha, this study examines the clinical characteristics, risk factors, and phylogenetics of the CHIKV epidemic in Kassala City.

67 Methodology/Principal Findings

A prospective cohort of 142 cases (102 adults, 40 children) were enrolled at Kassala Teaching Hospital in October 2018. Clinical information, socio-demographic data and sera samples were analysed to confirm diagnosis, characterise illness, and identify the viral strain. CHIKV infection was confirmed by real-time reverse transcription-PCR in 84.5% (120/142) of participants. Nine had concurrent CHIKV/Dengue virus (DENV) infection and 28.8% had a positive Rapid Diagnostic Test for malaria. Five percent had haemorrhagic symptoms including two children with life-threatening haemorrhage. One CHIKV-positive participant died with acute renal injury.

Ninety to 120 days post-illness, 63% of those followed-up were still experiencing arthralgia in one or more joints, and 11% remained moderately disabled using Rapid3 assessment. Phylogenetic analysis showed all CHIKV infections belonged to a single clade within the Indian Ocean Lineage (IOL) of the East/Central/South African (ECSA) genotype. History of contact with an infected person was the only socio-demographic factor associated with infection (p=0.01), suggesting that vector transmission in households is important.

81 Conclusions/Significance

The epidemic is estimated to have affected ~ 50% of Kassala City's population. Substantial vulnerability to CHIKV remains here and elsewhere in Sudan due to widespread *Aedes aegypti* presence and mosquito-fostering household water storage methods. This study highlights the importance of increasing awareness of the severity and socio-economic impact of CHIKV outbreaks and the need for urgent actions to reduce transmission risk in households.

87 Keywords: Chikungunya, disability, epidemiology, outbreak, Kassala, Sudan

4

89 Author summary [200w]

90 Chikungunya is an arboviral disease transmitted to humans by infected mosquitoes and characterised 91 by fever and arthralgia. Although it is generally considered a short self-limiting infection, long term 92 sequelae and severe disease are increasingly recognised. In 2018/19, Eastern Sudan experienced the 93 largest epidemic of Chikungunya in Africa to date, affecting approximately 500,000 people. We 94 undertook a prospective hospital-based cohort study of patients presenting with undifferentiated 95 febrile illness in Kassala city, Sudan, supported by next-generation sequencing. We confirmed that CHIKV was the dominant pathogen, with positive CHIKV RT-PCR in 85% of patients presenting during 96 97 the 7-day study period. Dengue virus was also circulating with nine CHIKV PCR-positive patients coinfected, and we identified high rates of Plasmodium falciparum malaria infection and CHIKV/malaria 98 99 co-infection. Genetic sequencing confirmed Indian Ocean Lineage of the East/Central/South African 100 CHIKV genotype. A substantial proportion of participants were admitted to hospital including children 101 with haemorrhage, reflecting the severe phenotype linked to this genotype. Increased understanding 102 of the health and economic burden of Chikungunya is needed, and recognition that severe and 103 occasionally fatal infection exists. With widespread presence of Ae. aegypti and household water 104 storage practices that encourage mosquito breeding, timely actions will be essential to prevent further 105 large outbreaks.

5

106 MAIN TEXT: 3876 words

107 INTRODUCTION

108 Chikungunya is often considered a mild illness and its public health impact underestimated in Africa
 109 and the Middle East despite the fact that greater severity and long-term sequelae have been reported
 110 increasingly in recent years.¹⁻³

First isolated in Tanzania in 1952,⁴ Chikungunya virus (CHIKV) was implicated in rural outbreaks and sporadic cases across Africa until 1980, when it effectively disappeared. In 2004, however, it reappeared with a vengeance in a pandemic that spread from Kenya to the Indian Ocean islands and Asia, causing millions of infections.^{5, 6} In central Africa, sizeable CHIKV outbreaks in cities signalled a major shift in transmission to urban settings.^{2, 3, 7-9}

Early symptoms of CHIKV are similar to many tropical febrile illnesses but it is differentiated by debilitating arthralgia, often bilaterally and in multiple joints. Other symptoms include headache, gastrointestinal problems, fatigue, asthenia, peripheral oedema and conjunctivitis.¹⁰ Although most cases improve after 1-2 weeks, recent outbreaks have seen higher incidences of severe illness, including sepsis and cardiac, renal, neurological, skin and ocular manifestations, and of longer-term effects including persistent pain, rheumatic symptoms, depression, and mood and sleep disorders.¹¹⁻ ¹⁶ A meta-analysis of chronic symptoms studies in 15 outbreak countries found 43% of cases had not

recovered at three months, and 21% unrecovered at 12 months. Long term neurodevelopmental delays have been reported in infants symptomatically infected through vertical transmission.^{17, 18} Apart from anti-inflammatory drugs, there is no treatment for Chikungunya and, as yet, no vaccine.¹⁹

Recent outbreaks have also challenged the view that CHIKV fatality is rare. Mortality of 10-48% were reported in the Reunion Island outbreak among cohorts of hospitalised patients.^{13, 16} Central nervous system Infections with fatal outcomes have been reported in the Americas.²⁰ Other locations have documented substantial rises in all-cause deaths during outbreak periods.²⁰

Hypotheses to explain these changes include persistent immune activation triggered by viral debris, improved surveillance and genetic mutation, particularly a new variant known as the Indian Ocean Lineage (IOL) which, since the 2004-2006 pandemic, has been linked to greater severity and the highest rates of non-recovery.²¹ IOL has also been linked to increased risk of outbreak as some forms contain a mutation that allows CHIKV to use the temperate-dwelling *Aedes albopictus* mosquito as a vector as well the tropical *Aedes aegypti*.^{5, 21}

In low-resource settings, outbreaks of undifferentiated febrile illness (UFI) are both common and a
 diagnostic challenge. The Federal Republic of Sudan has seen 12 major outbreaks of UFI since 2012,
 frequently associated with haemorrhage and high case fatality ratios²² and a range of high-

consequence infectious diseases are endemic or epidemic in Sudan. Crimean-Congo haemorrhagic 139 140 fever was recently identified as a common pathogen in a retrospective investigation of outbreaks in Darfur.²³ Yellow fever virus epidemics occur²⁴ and outbreaks of dengue fever are common.²⁵ The 141 Federal Ministry of Health (FMoH) maintains a sentinel surveillance system and supports individual 142 143 states with rapid response teams and enhanced diagnostic capability at the National Public Health 144 Laboratory (NPHL) in Khartoum.

145 In late July 2018, the sentinel surveillance in Kassala State (Figure 1) detected an increased frequency 146 of UFI and CHIKV was identified by the NPHL in the blood sample of a traveller to Kassala city from nearby Red Sea State. In mid-September reports of cases with more severe symptoms, including 147 haemorrhage, raised fears that another pathogen might be involved. Using a pre-prepared, locally and 148 149 internationally-approved protocol, FMoH and Kassala Teaching Hospital (KTH), supported by Kassala 150 University and the UK Public Health Rapid Support Team, deployed a small pre-trained study team of 151 clinical, epidemiology and laboratory staff to investigate the outbreak syndrome, confirm the outbreak pathogen, and sequence the outbreak strain. 152



153 **Figure 1: Study location**

Legend: Kassala state, located in Eastern Sudan, 600 km the capital city, Khartoum. covers an area of 42,282 km² and has a population 1.8 million inhabitants. Kassala City is the State capital with a population of ~ 400,000. Kassala Teaching Hospital is the State tertiary hospital and provides service for all patients referred from health centres and rural hospitals.

170 **METHODS**

- 171 The study was a prospective hospital-based observational cohort of consecutive patients presenting with UFI (case definition, Figure 2) at the KTH medical and paediatrics outpatient clinics departments 172 173 between 10th and 16th October 2018. Epidemiological information, clinical symptoms and laboratory
- 174 results were recorded at presentation on standardised pro-formas (Supporting Information 1). The
- sample size of 140 cases was informed by existing literature3 and feasible recruitment in the urgent 175
- 176 time frame (7 days).
- 177 Blood samples were drawn at initial assessment, and adults who responded to phone follow-up provided convalescent samples and completed the WHO-validated Routine Assessment of Patient 178
- Index Data 3 (RAPID3) disability and pain survey²⁶ 90-120 days later (Jan-Feb 2019). Children were not 179
- 180 asked to return due to common reluctance to allow blood-draw from healthy children, but outcome
- and duration of hospital stay were confirmed with parents. All contactable participants were given 181
- 182 their PCR test results.

183 Figure 2: Case definition used in Kassala Teaching Hospital

Individuals of any age or sex who come to the health facility with history of fever or a measured fever of >37.5°C (tympanic),

AND At least three of the following clinical features:

> Headache Lethargy **Breathing difficulties** Diarrhoea **Difficulty swallowing**

Anorexia Aching muscles or joints Vomiting Stomach pain Hiccups

7

OR: Bleeding of any kind

184

Patients with a positive malaria RDT should be enrolled if they fit the study syndrome as

185 Haematology (Mindaray 3000 Plus, China), biochemistry analysis (Biosystem BTS 310, Germany), and 186 malaria rapid diagnostic tests (RDT, SD Bioline, USA) were performed at admission on all participants: 187 malaria thick film examination was done for all children. Plasma samples were frozen at -80°C and 188 transported under liquid nitrogen to the NPHL in Khartoum where nucleic acid was extracted (QIAamp 189 Viral RNA Mini kit, Qiagen, Germany) and gRT-PCR performed to detect CHIKV RNA (RealStar Chikungunya RT-PCR Kit 2.0, Altona Diagnostics, Germany) using Rotor Gene Q or Corbett RG6000 190 thermocyclers. Exposure to CHIKV and DENV was assayed by anti-chikungunya and anti-dengue IgM 191 192 and IgG indirect ELISA (Euroimmun, Germany). Due to limited availability of anti-chikungunya IgM 193 ELISA kits, CHIKV PCR-negative samples were prioritised, followed by 69 CHIKV PCR-positives in order

8

194 of recruitment. An Ebolavirus qRT-PCR (RealStar Ebolavirus RT-PCR Kit 1.0, Altona Diagnostics, 195 Germany) was performed on samples from patients with bleeding symptoms.

196 All patient data were entered into encrypted software and analysed with STATA (StataCorp LLC, USA, 197 V14.2). Descriptive statistics are expressed as medians and Inter-Quartile Range (IQR) or means and 198 standard deviations (SD) for continuous variables, and frequencies and proportions for categorical variables. Fisher's exact, Chi², T-tests and Spearman's Rank Order coefficients were used to assess 199 200 association and correlation related to CHIKV PCR result. Significance was set at p<0.05.

201 Ethical approval was granted by the FMOH Technical Review Board, and Ethics Committee of Karary University, Khartoum and the London School of Hygiene & Tropical Medicine (Ref: 11930). All 202 203 participants or parents/guardians of children aged under 18 years provided written informed consent.

204 **Genetic sequencing**

205 Complementary DNA (cDNA) was prepared and Sequence Independent Single Primer Amplification 206 (SISPA) performed prior to library preparation using Oxford Nanopore kits (SQK-LSK108). Sequencing 207 on flow cells (FLO-MIN106) was done using the MinION (Oxford Nanopore Technologies) as previously described.²⁷ Thirty samples were sequenced at NPHL and analysed using Albacore 1.2 to basecall, 208 Mash Screen²⁸ was used to identify the most closely matched genome on Genbank and a reference 209 guided genome assembly constructed as described previously.²⁷ The first seven sequences were used 210 211 to construct a basic phylogenetic analysis using MEGA version 6 (results not shown) in order to identify 212 the Kassala strain in Sudan. With FMoH permission, sample aliquots were also transferred to PHE 213 Porton and sequenced using the same methods. The resulting viral genetic sequences were sent to 214 Oxford University Department of Zoology for phylogenetic analysis.

Whole genome sequences were aligned with publicly available complete CHIKV genomes belonging 215 to the ECSA genotype using MAFFT v7.450 implemented in Geneious R8.²⁹ A maximum likelihood (ML) 216 phylogenetic tree was estimated using RAxML 8.0³⁰ under a GTR substitution model with a Gamma 217 model of among-site rate heterogeneity. The estimated ML phylogeny was midpoint rooted, and node 218 219 support was assessed through 100 ML bootstrap replicates. The geographic location and amino acid 220 identity at site E1-226 of each sequence were annotated in the tree to explore the phylogenetic 221 distribution of those traits.

222

223 RESULTS


224 A total of 102 adults and 42 children (<18 years) were recruited over seven days, of which two cases 225 without samples were excluded. 11 patients or their guardians refused to participate, and 2 patients 226 dead on arrival were not included as sampling was not possible (Figure 3).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199976; this version posted September 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

9

227 Figure 3: Flow diagram of study participants and virological findings



228

Participants were aged 4 months to 70 years (mean 27 years, SD 17.6); 47.9% were female, none were
pregnant (Table 1). Almost half (46.1%, 65/141) were people likely to spend more time in a household
compound (e.g. housewives, unemployed, retired, children under 5). Median household size was 8.
Two-thirds of participants lived in brick/concrete houses with own well and sanitation, the remainder
lived in less permanent material structures with shared water and sanitation. A third kept animals in
their compound.

10

236 Table 1: Participant characteristics by Chikungunya qRT-PCR result

	total	CHKV pos (n=120)	%	CHKV neg (n=22)	%
Sex					
Female	47.9%	56	82.3	12	17.7
Male	52.1%	64	86.5	10	13.5
Age (y), median [IQR]		22	14-40	37	21-54
Age Group (y) (n=141)					
<2	7	7	5.9	0	0.0
2-4	6	5	4.2	1	4.5
5-14	24	22	18.5	2	9.1
15-29	51	46	38.7	5	22.7
30-49	33	26	21.8	7	31.8
50+	20	13	10.9	7	31.8
Occupation (n=141)					
< 5 child	13	12	10.0	1	4.8
Schoolchild/student	49	43	35.8	6	28.6
Housewife	31	26	21.7	5	23.8
Farmer/Outdoor worker	15	12	10.0	3	14.3
Professional/Business	7	7	5.8	0	0.0
Health worker	5	3	2.5	2	9.5
Retired/unemployed	21	17	14.2	4	19.0
Median household size (IQR) n=102	8	8	6-11	7	5-9
Missing data: age 1, occupation 1, # in	househola	40			

237 238

Most participants came from Kassala City sectors 2,3, 4 and 5 on the banks of the seasonal River Gash 239

240 (69%, 80/116), coinciding with areas of greatest flooding in the 2018 rainy season, and with highest

241 case reports during the epidemic (Figure 4). A further 26% (30/116) were from rural areas up to 1.5

242 hours' drive away.


medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199976; this version posted September 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4: Distribution of all reported Chikungunya cases in Kassala City and surrounds, Aug – Nov

245 2018 (n=19,902)

246



247

Credit: Kassala State Ministry of Health Epidemiology Unit, Epidemic Report Presentation, 5 Nov. 2018
 Circles represent City Sectors 2,3,4,& 5

250

251 Clinical presentation

- 252 Median delay from symptom onset to presentation was 2 days (IQR 1-4, n=139) with no difference
- by CHIKV diagnosis or age (Table 2). Sixteen (26.6%) participants were admitted (4 adults, 12
- children). Children were more likely to be admitted than adults and for longer: a mean of 4.7 days
- compared to 2.3 days for adults (p=0.04).
- 256 Most common symptoms at presentation among CHIKV PCR-positive participants were fever (97.5%),
- 257 headache (88.2%), fatigue (82.5%), muscle, joint and back pain (66.0%, 83.8%, 50.9% respectively),
- loss of appetite (40.4%) and vomiting (40.2%); patients who were CHIKV PCR-negative had similar
- 259 presenting symptoms. Participants co-infected with CHIKV and DENV were more likely to present with
- 260 back pain than those with CHIKV alone (p=0.003). Five percent (6/120) of CHIKV PCR-positive
- 261 participants reported bleeding, including haematemesis (4), oral bleeding (2), epistaxis (3), petechiae

- 262 (1), haemoptysis (1) and melaena (1). Ten percent of CHIKV PCR-positive adults (18/78) were
- hypotensive (systolic blood pressure <100 mmHg) with seven also being tachycardic (pulse >100). 263
- 264

Table 2: Clinical symptoms and Ct values of participants at presentation by CHIKV gRT-PCR result 265 266 (n=142)

	CHIKV pos	%	CHIKV neg	%
Days from onset to presentation	2	IQR 1-4	2	IQR 1-5
Symptoms at presentation				
Fever/history of fever	117	97.5	22	100.0
Any bleeding	6	5.0	1	4.8
Headache	97	80.8	17	85.0
Joint pain	93	77.5	15	75.0
Fatigue	85	70.8	17	81.0
Muscle pain	66	55.0	16	76.2
Back pain	55	45.8	9	42.9
Loss of appetite	46	38.3	6	28.6
Vomiting	45	37.5	8	38.1
Abdominal pain	32	26.7	8	38.1
Lack of strength	25	20.8	4	100.0
Dizziness	18	15.0	3	14.3
Chest pain	17	14.2	3	15.0
Cough	17	14.2	2	9.5
Rash	13	10.8	2	9.5
Diarrhoea	11	9.2	2	10.0
Dysphagia	9	7.5	3	15.0
Dehydration	9	7.5	1	33.3
Shortness of breath	7	5.8	2	10.0
Conjunctivitis	7	5.8	3	15.0
Sore throat	6	5.0	0	0.0
Confusion	3	2.5	0	0.0
PCR Cycle Threshold				
High (Ct <20)	33	27.5	-	
Moderate (Ct 20-29)	24	20.0	-	
Low (Ct 30-38)	63	52.5	-	
Other pathology				
Malaria positive (RDT)	34/118	28.8	5/22	22.7
DENV positive (PCR)	9/120	7.5	3/22	13.6
*Missing: onset date 3; malaria RDT 2;				

267

268 Laboratory results

Of 142 participants, 120 were confirmed positive for CHIKV infection by qRT-PCR, giving the case 269 270 definition used a positive predictive value of 84.5%. CHIKV PCR cycle threshold (Ct) values ranged from 12-37 (mean 27.3, SD 7.6); over a quarter (27.5%) had a Ct value corresponding with a high viral load 271 (Ct<20) (Table 2). A significant correlation existed between Ct value and both day of illness (Spearman 272 273 r=0.37, p<0.001) and lymphocyte count (r=0.23, p=0.012); no other significant correlations were 274 found. Prolonged viremia was observed in seven CHIKV PCR-positive who presented 10 days after

13

275 disease onset. Of 91 participants tested for CHIKV IgM antibodies, 45 were positive including 14 276 participants who were negative on CHIKV PCR (Figure 3).

277 Nineteen percent of CHIKV PCR-positive participants (23/120) were coinfected with DENV either by 278 PCR or IgM-ELISA. Of all samples (CHIKV-positive and negative), 81.6% (115/141) were DENV IgG-279 positive indicating previous infection. Of the 118 CHIKV PCR-positive participants with malaria RDT 280 result, 28.8% were positive, with the highest proportion in those aged 15-29 years. No participants 281 were co-infected with all three pathogens.

282 Among participants with matched CHIKV PCR and ELISA results, 31/69 PCR-positive were also IgM-283 positive, and 34/119 (28.6%) were CHIKV IgG positive (Figure 3). Participants who were CHIKV positive 284 on both PCR and IgM presented later in illness course than those who were CHIKV PCR-positive and 285 IgM-negative (p<0.001). This finding was replicated with CHIKV PCR & IgG-positive patients who 286 presented later than CHIKV IgG-negative patients (p=0.002).

There was a significant difference in mean haematocrit levels between CHIKV PCR-positive (mean 287 288 35.9, SD=6.27) and negative participants (mean 38.9, SD=7.41, p=0.05), but no other significant 289 differences in blood chemistry. Heart rate and blood pressure were similar in both groups. In the 290 CHIKV PCR-positive cohort median haematology and biochemistry results were all within normal 291 ranges (Table 3). Leucopenia (white blood count < 4 x $10^9/L$) was observed in 29% (35/120) and 292 lymphopenia (< 1 x 10⁹/L) observed in 50.7% (61/120). Elevated AST (>40IU/L) was observed in 22.5% 293 (27/120) with six participants at levels> 100 IU/L (max 259 IU/L). ALT levels >51 IU/L were seen in 294 seven participants with four recording levels >100 (max 150 IU/I). Acute kidney injury was observed 295 in one fatal case. Platelet counts $< 100 \times 10^{9}$ /L were recorded in 23/120 CHIKV PCR-positive 296 participants, of whom 14/23 were also malaria RDT positive and none DENV PCR positive. Platelet 297 counts $< 50 \times 10^9$ /L were observed in six participants, three of whom also had positive malaria RDT.

	CHIKV+	SD	n	CHIKV-	SD	n
Heart rate (beats/min)	91.2	19.2	114	83.5	15.8	21
Respiratory rate	20.4	2.9	12	18.0	n/a	1
Systolic pressure	102.9	20.2	78	106.3	12.5	20
Diastolic pressure	68.0	13.1	78	70.2	7.5	20
Haemoglobin (g/dL)	11.6	2.2	120	12.5	2.5	22
Haematocrit (%)*	35.9	6.3	119	38.9	7.4	22
WBC (10 ³ /uL)	6.1	3.1	120	4.8	2.2	22
Lymphocytes (10 ³ /uL)	2.1	2.4	118	2.9	6.6	22
Platelets (10 ⁹ /L)	227.0	143.3	120	190.6	131.0	22
Nitrogen oxide	3.8	2.0	113	2.9	1.7	22
Urea (mg/dL)	24.8	14.9	119	26.1	11.3	22
Creatinine (mg/dL)	0.8	0.7	119	0.9	0.2	22
Bilirubin	0.7	1.5	119	0.9	1.3	22
AST (IU/L)	36.0	33.9	119	28.2	17.4	22
ALT (IU/L)	23.1	23.4	118	21.5	14.4	22
Albumin	14.9	6.8	69	17.6	6.4	17

299 Table 3: Mean clinical parameters of participants at presentation by CHIKV gRT-PCR result

301

302 Severe or fatal disease

303 The study recruited one case with a fatal outcome - a male teacher aged 52 transferred to KTH 13 days 304 after onset of symptoms. He was CHIKV PCR-positive with a Ct of 30 and no coinfection. At admission 305 he had petechiae and minor bruising but no other evidence of bleeding. He died from sepsis 306 complicated by disseminated intravascular coagulation and acute kidney injury (Blood/Urea/Nitrogen 307 (BUN) 154 mg/dL, creatinine 7.8 mg/dL, AST 259 IU/L, ALT 59 IU/L, platelets 111 x 10⁹/L).

308 Two children *in extremis* with significant haemorrhage were recruited at the paediatric department. 309 Both were CHIKV PCR-positive without coinfection. The 16-year-old was admitted on day 2 of illness 310 with a history of fatigue, headache, back pain, anorexia, oral mucosal haemorrhage, and profuse epistaxis. He was in shock (pulse 120, BP 84/50, respiratory rate 25) with a platelet count of 10×10^9 /L, 311 Hb 12.5 g/dL, WBC 10.5 x 10³/uL, HCT 38.9%, AST 47 IU/L, ALT 24 IU/L, BUN 26 mg/dL, creatinine 0.8 312 313 mg/dL and CHIKV PCR Ct 29.63. He was resuscitated with blood and platelet transfusion, underwent nasal packing, and was discharged after 15 days. The second child aged 7 years presented on day 0 of 314 315 illness with epistaxis, haematemesis, melaena, bruising and anorexia. Her pulse was 130 and Hb 10.2 316 g/dL, WBC 4.6 x 10³/uL, platelet count 20 x 10⁹/L, HCT 30.7%, urea 22 mg/dL, creatinine 0.5 mg/dL, AST 175 IU/L, ALT 129 IU/L and CHIKV PCR Ct of 26.8. She was also resuscitated with blood and 317 318 platelets and discharged well after nine days admission.

15

320 Factors associated with CHIKV positivity

321 The mean age of CHIKV PCR-positive patients was significantly less than CHIKV PCR-negative patients 322 (p=0.003). CHIKV PCR-positives were also more likely to report exposure to someone who was ill 323 (p=0.01) but as CHIKV is not transmitted person-to-person, this finding likely relates to being in the 324 same vector environment. No associations were found with any other exposure. Compared to those with a single infection, CHIKV/DENV coinfected participants had higher mean systolic blood pressure 325 326 (p=0.03) haemoglobin (p=0.01), haematocrit (p=0.03), bilirubin (p=0.002) and albumin (p=<0.001).

327 **Convalescent follow-up**

328 Thirty (29.7%) of the 102 adult participants could be followed-up 90-120 days after enrolment, 29 329 (28.7%) refused, and 42 (41.6%) could not be reached. Parents of 30 of the 40 child participants 330 responded to contact. All 60 followed-up were CHIKV PCR-positive at baseline. Sixteen (26.6%) had 331 been admitted to hospital of whom four were children admitted for more than seven days (Table 4). 332 Respondents were more likely to be admitted if they had bleeding (p=0.016), vomiting (p=0.014), or a positive malaria RDT (p=0.001). Of adults followed-up 43.3% (13/30) had spent 1-2 weeks off work 333 334 and 20.0% (6/30) 2 or more weeks. Twenty-three of the 30 convalescent samples collected (76.7%) 335 were IgG positive; 13 had seroconverted since recruitment and seven remained IgG negative.

336 **Chronic disability**

Nineteen of the 30 adults followed up at 90-120 days (63%) were still experiencing arthralgia, most 337 338 frequently in the knee (46.7% 14/30), ankle (36.7% 11/30) wrist (30.0% 9/30) and shoulder (26.7% 8/30). Asked to rank pain and general wellbeing over the previous week on a scale where 10 was the 339 340 most pain/most unwell, respondents reported a median pain score of 4 (IQR 2-5) and median 341 wellbeing score of 7 (IQR 3-8). A third (36.6%, 11/30) indicated their pain was greater or the same as during the acute phase of their illness, and even those with less pain than before reported continuing 342 to take painkillers, anti-inflammatories, corticosteroids, or all three, for their condition. In total, 60% 343 continued to take medication. 344

345 Of the 28 respondents who completed the RAPID3 disability survey, three-quarters reported a continuing effect on day-to-day activities, including difficulties getting out of bed (28%), walking 2 346 347 miles (35%) and getting in and out of a vehicle (17%), while 10-15% reported difficulty with activities 348 such as turning on taps, bending and sleeping well. Rapid3 scaling indicated that, 90-120 days after their acute illness, 10.7% (3/28) of respondents were experiencing moderately severe disability and 349 350 60.7% (17/28) low severity disability. The remaining eight (28.6%) respondents were considered 351 nearly recovered. Neither level of viremia on admission, nor pre-existing conditions such as diabetes,

16

- 352 hypertension and osteoarthritis, were associated with level of residual disability, or duration of
- 353 absence from work.

354 Table 4: Impact of CHIKV infection on work and disability 90-120 days after acute infection

	Adults (n=101)	%/SD	Children (n=40)	%/sd	p (exact)
Follow-up response rate	30	29.7%	30	75.0%	
Hospital care (n=30)					
Discharged the same day	26	86.7%	18	60.0%	
Admitted for at least 1 day	4	13.3%	12	40.0%	p=0.039
Mean days admitted	2.3	sd 1.3	4.7	sd 4.1	
Absence from work					
< 1 week	11	36.7%			
1-2 weeks	13	43.3%			
3-4 weeks	4	13.3%			
>4 weeks	2	6.7%			
RAPID3 disability score (n=28)					
Near remission	8	28.6%			
Low disability	17	60.7%			
Moderate disability	3	10.7%			
Current presence of pain (n=30)	19	63.3%			
Location of pain (multiple possible	2)				
Knee	14	46.7%			
Ankle	11	36.7%			
Wrist	9	30.0%			
Shoulder	8	26.7%			
Fingers	7	23.3%			
Median pain perception score	4	IQR 2-5			
Median wellbeing score	7	IQR 3-8			

- 355 356 Note: Pain perception and wellbeing are scored on a 0-10 scale with 10 being the worst pain and
- 357 feeling the worst
- [Data access link to be added] 358

359 **Genetic analysis**


360 Virus genetic sequencing found that all CHIKV PCR-positive samples belonged to a single monophyletic cluster in the Indian Ocean Lineage (IOL) of the ECSA genotype of CHIKV (Figure 4). This clade is distinct 361 362 from those previously identified in Western and Central Africa, suggesting that the Kassala outbreak 363 was caused by an independent introduction of an IOL strain into the region. This might have occurred 364 via the Middle East or Indian Subcontinent since the Kassala sequences are closely related to (i) the 365 Henan and Shivane variants identified in China and Hong Kong, which originated in returning travellers from India/Pakistan, and (ii) a clade that includes sequences from a 2016 outbreak in Pakistan and 366 367 other sequences from India and Bangladesh. Absence of the A226V mutation - a mutation associated with the capacity of the virus to infect Ae. albopictus^{31, 32} confirms Ae. aegypti as the most likely 368 369 outbreak vector species. (Figure 5)

370 [Genbank accession numbers to be added]

17


371 Figure 5: Maximum likelihood phylogenetic tree of the ECSA genotype and its two distinct lineages

372 showing the location of the Kassala 2018/19 strain



373

374 Legend: Maximum likelihood phylogenetic tree of the East/Central/South African (ECSA) genotype and its two distinct lineages: the Indian Ocean Lineage (IOL) and the Middle African/ South American 375 (MASA) lineage. The monophyletic Kassala epidemic clade groups with sequences that originate from 376 377 the Middle East and India and represents a distinct lineage from other African CHIKV variants. Node 378 support values were evaluated using 100 bootstrap replicates and are illustrated using colour at nodes (with white representing 0 and black representing 100). The 2016 Mandera outbreak also represents 379 380 a possible introduction from the Indian subcontinent and appears to be an independent event from the Kassala epidemic. Both outbreaks share Ae. aegypti adaptive variant at site A226. 381 382



383

384 Figure 5: CHIKV ECSA phylogenetic tree showing the amino acid identity at site 226 of the E1 protein, associated with viral adaptation to different vector species. Viruses containing the A226 variant infect 385 386 Ae. aegypti more efficiently, while viruses containing the V226 variant more efficiently infect Ae. 387 albopictus. The evolution of this trait is mapped (through a parsimony reconstruction) on the tree in 388 different colours.

389

390 DISCUSSION

Our phylogenetic analysis suggests the unprecedented Chikungunya epidemic that took place in the 391 392 Eastern states of Sudan in 2018-19 was caused by an independent introduction of a CHIKV IOL virus, of the same strain responsible for the outbreaks observed worldwide during 2004-2007 and linked to 393 394 more severe manifestations of CHIKV disease.

Even at the conservative estimate^{33, 34} of 487,600 cases, the epidemic that occurred in Kassala and Red 395 396 Sea States is the largest outbreak of Chikungunya in Africa and the Middle East to date, and there are 397 multiple reasons to suspect substantial under-reporting and underdiagnosis. Reasons for this include 398 reporting through sentinel surveillance sites normally intended to raise an alert rather than capture 399 every case, population reluctance to seek medical attention at hospitals due to cost and limited

19

400 treatment options, limited diagnostic resources, lack of data collection in private clinics, and the range401 of CHIKV illness severity.

402 Made possible by the established research collaboration between the FMoH and the UK Public Health 403 Rapid Support Team on outbreak response, this study utilised pre-approved protocols, pre-trained 404 staff and, for the first time within Sudan, next generation sequencing technology in-country. We 405 confirmed that CHIKV was the dominant pathogen responsible for the outbreak, that DENV was also 406 circulating with 1 in 5 CHIKV positive patients co-infected, and importantly that there were a high 407 frequency of falciparum malaria transmission and of CHIKV/malaria co-infection.

- 408 The cohort recruited were young (median age 27) and largely presented with non-specific febrile 409 symptoms plus poly-articular joint pain. The substantial proportion (26%) admitted to hospital, 410 however, reflects high frequencies of co-infection and the potential for haemodynamic disturbance in 411 adults, and other manifestations of a severe phenotype observed in a subset of patients. As we have 412 described, 5% of patients with CHIKV (malaria and DENV negative) had evidence of bleeding and loss of haemostasis. Two children in particular were gravely unwell with life-threatening haemorrhage 413 414 associated with severe thrombocytopenia and need for blood product resuscitation, while one adult 415 died of multi-organ failure including acute kidney injury.
- Severe and fatal CHIKV infection has been reported previously during outbreaks challenging the misconception that it is only a mild self-limiting diseases.^{13, 35} Increased risk of severe disease has been suggested in extremes of age (neonates and > 65 years) and those with underlying medical problems including immunosuppression.^{10, 15} Severe disease has been associated with neurological complications such as acute flaccid paralysis and Guillain-Barré syndrome.³⁶⁻³⁸ Brazil, Reunion Island and India all reported high case fatality and excess deaths during their epidemics, ^{12, 13, 16, 39, 40} though fatality is still considered rare, occurring in less than 1 in 1000 cases.
- These findings are consistent with the severe phenotype of CHIKV we observed in Kassala, including a one confirmed CHIKV PCR-positive death and life-threatening bleeding due to loss of haemostasis with thrombocytopenia. Additionally, the high frequency of *P.falciparum* infection detected underpins the importance of both malaria diagnostics and public messaging in malaria-endemic settings when chikungunya outbreaks occur.
- 428 Our study was biased towards more severe cases due to hospital-based recruitment and a low 429 response rate among and lack of a control for participants followed up within 90-120 days. However, 430 our findings that 63% of respondents had persistent pain three to four months after acute illness are 431 similar to those of a case-controlled study on La Reunion Island. This study found 53% of IOL-strain 432 CHIKV-positive participants reported twice as much pain compared to controls 12 months after their 433 illness.⁴¹ Our findings were also similar to those of a meta-analysis of chronic disability across all CHIKV

20

434 strains which found on average 52% of IOL-strain patients were still disturbed by symptoms at three months, compared to 39% of Asian lineage and 14% of ECSA group patients.²¹ 435

436 Our finding that the only significant risk factor for contracting CHIKV was proximity to a case suggests 437 identifying and supporting vector control measures acceptable to the community should be a priority 438 for public health authorities seeking to prevent future CHIKV and other Aedes-transmitted epidemics 439 in Sudan. Entomological research carried out by Kassala University in 2014/15 showed high Ae. aegypti 440 density across the city and a high proportion of households storing water in their compounds in unprotected clay pots.⁴²⁻⁴⁴ In 2018 the situation was exacerbated by intense seasonal rainfall which 441 displaced 50,000 residents and flooded many areas, a situation that is being seen again in 2020. 442

443 Measures such as improved water infrastructure, covered water storage containers, and increased 444 population awareness of the importance of preventing mosquitoes from breeding in household compounds are important.⁴² Heightened vector surveillance is also needed to monitor for presence of 445 446 Ae. albopictus, which could prompt further outbreaks of different CHIKV strains, as well as 447 investigation of the potential role in the sylvatic cycle of the large population of Macaques monkeys 448 which live close to residential areas.

449 Finally, but importantly, it is essential that State Ministries of Health throughout Sudan enhance their 450 risk communication and public information strategies around Chikungunya to underline that severe 451 and occasionally fatal infection exists. The epidemic we describe caused substantial health and 452 economic burden for the affected populations. With widespread presence of Ae. aegypti and a similar 453 water storage practices throughout Sudan, timely actions will be needed to prevent another large 454 outbreak in the near future.

455

Acknowledgements and disclaimers 456

457 The study team appreciates the collaboration of the leadership of the University of Kassala, Kassala 458 Teaching Hospital, Kassala State Ministry of Health, Federal Ministry of Health Directorate of Health 459 and Epidemics Control Directorate, and the National Public Health Laboratory. We also appreciate 460 the efforts of the International Severe Acute Respiratory and Emerging Infection Consortium to 461 create generic protocols including the Clinical Characterisation Protocol for Severe Emerging Infections from which our study was adapted.⁴⁵ The UK Public Health Rapid Support Team is funded 462 by UK aid from the Department of Health and Social Care and is jointly run by Public Health England 463 464 and the London School of Hygiene & Tropical Medicine. The University of Oxford and King's College 465 London are academic partners. The views expressed in this publication are those of the authors and

medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199976; this version posted September 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

21

466 not necessarily those of the National Health Service, the National Institute for Health Research, or

the Department of Health and Social Care.

468

469 **REFERENCES**

Bonney JH, Osei-Kwasi M, Adiku TK, Barnor JS, Amesiya R, Kubio C, Ahadzie L, Olschlager S,
 Lelke M, Becker-Ziaja B, Pahlmann M, Gunther S. Hospital-based surveillance for viral hemorrhagic
 fevers and hepatitides in Ghana. PLoS neglected tropical diseases. 2013;7(9):e2435

Russo G, Subissi L, Rezza G. Chikungunya fever in Africa: a systematic review. Pathogens and
 Global Health. 2020 2020/04/02;114(3):111-9

475 3. Humphrey JM, Cleton NB, Reusken CBEM, Glesby MJ, Koopmans MPG, Abu-Raddad LJ.

476 Urban Chikungunya in the Middle East and North Africa: A systematic review. PLoS neglected
477 tropical diseases. 2017;11(6):e0005707

478 4. Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika territory, in
479 1952–1953. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1955

480 1955/01/01/;49(1):28-32

481 5. Ng LC, Hapuarachchi HC. Tracing the path of Chikungunya virus--evolution and adaptation.
482 Infect Genet Evol. 2010 Oct;10(7):876-85

483 6. Rossi G, Karki S, Smith RL, Brown WM, Ruiz MOH. The spread of mosquito-borne viruses in
484 modern times: A spatio-temporal analysis of dengue and chikungunya. Spatial and Spatio-temporal
485 Epidemiology. 2018 2018/08/01/;26:113-25

486 7. Leroy EM, Nkoghe D, Ollomo B, Nze-Nkogue C, Becquart P, Grard G, Pourrut X, Charrel R,
487 Moureau G, Ndjoyi-Mbiguino A, De-Lamballerie X. Concurrent chikungunya and dengue virus
488 infections during simultaneous outbreaks, Gabon, 2007. Emerging infectious diseases.
489 2009;15(4):591-3

490 8. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re491 emerging infectious disease. Clinical infectious diseases : an official publication of the Infectious
492 Diseases Society of America. 2009 Sep 15;49(6):942-8

9. Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, Drexler JF, Vasilakis N,
Lourenco-de-Oliveira R, Weaver SC, Kohl A, de Lamballerie X, Failloux AB, Brasil P, Busch M, Diamond
MS, Drebot MA, Gallian P, Jaenisch T, LaBeaud AD, Lecuit M, Neyts J, Reusken CB, Ribeiro GS, Rios M,
Rodriguez-Morales AJ, Sall A, Simmons G, Simon F, Siqueira AM. GloPID-R report on chikungunya,
o'nyong-nyong and Mayaro virus, part 5: Entomological aspects. Antiviral research. 2020
2020/02/01/;174:104670

499 10. van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of
500 chikungunya virus disease: A systematic review. Travel medicine and infectious disease. 2017 Jan 501 Feb;15:8-22

50211.Paixão ES, Teixeira MG, Rodrigues LC. Zika, chikungunya and dengue: the causes and threats503of new and re-emerging arboviral diseases. BMJ Global Health. 2018;3(Suppl 1):e000530

504 12. Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A, 505 Herrero LJ, Zaid A, Ng LFP, Mahalingam S. Chikungunya virus: an update on the biology and

pathogenesis of this emerging pathogen. The Lancet Infectious Diseases. 2017;17(4):e107-e17

Rajapakse S, Rodrigo C, Rajapakse A. Atypical manifestations of chikungunya infection.
 Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010 2010/02/01/;104(2):89-96

Mansactions of the Royal Society of Hopical Medicine and Hygiene. 2010 2010/02/01/,104(2):85-50
 Mehta R, Gerardin P, de Brito CAA, Soares CN, Ferreira MLB, Solomon T. The neurological

complications of chikungunya virus: A systematic review. Reviews in medical virology.
2018;28(3):e1978-e

512 15. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P,

513 Germonneau P, Quatresous I. Atypical Chikungunya virus infections: clinical manifestations,

514 mortality and risk factors for severe disease during the 2005–2006 outbreak on Réunion.

515 Epidemiology and Infection. 2009;137(4):534-41

516	16. Lemant J, Boisson V, Winer A, Thibault L, André H, Tixier F, Lemercier M, Antok E, Cresta MP,
517	Grivard P, Besnard M, Rollot O, Favier F, Huerre M, Campinos JL, Michault A. Serious acute
518	chikungunya virus infection requiring intensive care during the reunion island outbreak in 2005–
519	2006*. 2008;36(9):2536-41
520	17. Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child
521	transmission of Chikungunya virus: A systematic review and meta-analysis. PLoS neglected tropical
522	diseases. 2018;12(6):e0006510
523	18. Gérardin P, Sampériz S, Ramful D, Boumahni B, Bintner M, Alessandri J-L, Carbonnier M,
524	Tiran-Rajaoefera I, Beullier G, Boya I, Noormahomed T, Okoï J, Rollot O, Cotte L, Jaffar-Bandjee M-C,
525	Michault A, Favier F, Kaminski M, Fourmaintraux A, Fritel X. Neurocognitive Outcome of Children
526	Exposed to Perinatal Mother-to-Child Chikungunya Virus Infection: The CHIMERE Cohort Study on
527	Reunion Island. PLoS neglected tropical diseases. 2014;8(7):e2996
528	19. Innovations CfEP. The world needs a chikungunya vaccine [Accessed 05 Aug 2020]. Available
529	from: https://cepi.net/news_cepi/the-world-needs-a-chikungunya-vaccine/.
530	20. Lima STSd, Souza WMd, Cavalcante JW, da Silva Candido D, Fumagalli MJ, Carrera J-P,
531	Simões Mello LM, de Carvalho Araújo FM, Cavalcante Ramalho IL, de Almeida Barreto FK, de Melo
532	Braga DN, Simião AR, Miranda da Silva MJ, Oliveira RdMAB, Lima CPS, Sousa Lins Cd, Barata RR, Melo
533	MNP, de Souza MPC, Franco LM, Távora FRF, Queiroz Lemos DR, Alencar CHMd, Jesus Rd, Souza
534	Fonseca Vd, Dutra LH, Abreu ALd, Araújo ELL, Ribas Freitas AR, Gonçalves Vianez Júnior JLdS, Pybus
535	OG, Moraes Figueiredo LT, Faria NR, Teixeira Nunes MR, Góes Cavalcanti LPd, Miyajima F. Fatal
536	outcome of chikungunya virus infection in Brazil. Clinical Infectious Diseases. 2020
537	21. Paixao ES, Rodrigues LC, Costa M, Itaparica M, Barreto F, Gerardin P, Teixeira MG.
538	Chikungunya chronic disease: a systematic review and meta-analysis. Transactions of the Royal
539	Society of Tropical Medicine and Hygiene. 2018 Jul 1;112(7):301-16
540	22. Ashcroft J, Gannon B, Bower H, Hornsey E, Knight M, Whitworth J, Bausch DG. The UK public
541	health rapid support team: a novel programme integrating outbreak response, operational research,
542	and capacity building. Access Microbiology. 2019;1(1A):-
543	23. Bower H, El Karsany M, Alzain M, Gannon B, Mohamed R, Mahmoud I, Eldegail M, Taha R,
544	Osman A, Mohamednour S, Semper A, Atkinson B, Carter D, Dowall S, Furneaux J, Graham V, Mellors
545	J, Osborne J, Pullan ST, Slack GS, Brooks T, Hewson R, Beeching NJ, Whitworth J, Bausch DG, Fletcher
546	TE. Detection of Crimean-Congo Haemorrhagic Fever cases in a severe undifferentiated febrile illness
547	outbreak in the Federal Republic of Sudan: A retrospective epidemiological and diagnostic cohort
548	study. PLoS neglected tropical diseases. 2019;13(7):e0007571
549	24. Markoff L. Yellow fever outbreak in Sudan. The New England journal of medicine.
550	2013;368:689-91
551	25. World Health Organisation. Dengue Fever - Republic of the Sudan 2019 [accessed 1 January
552	2020]. Available from: https://www.who.int/csr/don/22-november-2019-dengue-sudan/en/.
553	26. American College of Rheumatology. Routine Assessment of Patient Index Data 3 (RAPID3)
554	[Accessed Oct 2018]. Available from:
555	https://www.rheumatology.org/Portals/0/Files/RAPID3%20Form.pdf.
556	27. Kafetzopoulou LE, Efthymiadis K, Lewandowski K, Crook A, Carter D, Osborne J, Aarons E,
557	Hewson R, Hiscox JA, Carroll MW, Vipond R, Pullan ST. Assessment of metagenomic Nanopore and
558	Illumina sequencing for recovering whole genome sequences of chikungunya and dengue viruses
559	directly from clinical samples. Euro surveillance : bulletin Europeen sur les maladies transmissibles =
560	European communicable disease bulletin. 2018;23(50):1800228
561	28. Ondov BD, Starrett GJ, Sappington A, Kostic A, Koren S, Buck CB, Phillippy AM. Mash Screen:
562	high-throughput sequence containment estimation for genome discovery. Genome biology. 2019
563	2019/11/05;20(1):232
564	29. Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version 7:
565	Improvements in Performance and Usability. Molecular Biology and Evolution. 2013;30(4):772-80
566	30. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
567	phylogenies. Bioinformatics. 2014;30(9):1312-3

medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199976; this version posted September 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

568 Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A Single Mutation in Chikungunya 31. 569 Virus Affects Vector Specificity and Epidemic Potential. PLOS Pathogens. 2007;3(12):e201 570 Lindh E, Argentini C, Remoli ME, Fortuna C, Faggioni G, Benedetti E, Amendola A, Marsili G, 32. 571 Lista F, Rezza G, Venturi G. The Italian 2017 Outbreak Chikungunya Virus Belongs to an Emerging 572 Aedes albopictus-Adapted Virus Cluster Introduced From the Indian Subcontinent. Open forum 573 infectious diseases. 2018;6(1):ofy321-ofy 574 Hsu CH, Cruz-Lopez F, Vargas Torres D, Perez-Padilla J, Lorenzi OD, Rivera A, Staples JE, Lugo 33. 575 E, Munoz-Jordan J, Fischer M, Garcia Gubern C, Rivera Garcia B, Alvarado L, Sharp TM. Risk factors 576 for hospitalization of patients with chikungunya virus infection at sentinel hospitals in Puerto Rico. 577 PLoS neglected tropical diseases. 2019;13(1):e0007084-e 578 34. Dorleans F, Hoen B, Najioullah F, Herrmann-Storck C, Schepers KM, Abel S, Lamaury I, Fagour 579 L, Cesaire R, Guyomard S, Troudard R, Adelaide Y, Romagne MJ, Davidas M, Rochais S, Boa S, de 580 Saint-Alary F, Preira A, Saint-Martin P, Vaidie A, Melin M, Daudens-Vaysse E, Rosine J, Blateau A, 581 Carvalho L, Septfons A, Paty MC, Leduc G, Cassadou S, Ledrans M, Cabie A. Outbreak of Chikungunya 582 in the French Caribbean Islands of Martinique and Guadeloupe: Findings from a Hospital-Based 583 Surveillance System (2013-2015). Am J Trop Med Hyg. 2018 Jun;98(6):1819-25 584 Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. 35. 585 Nature Reviews Rheumatology. 2019 2019/10/01;15(10):597-611 586 36. Sá PKdO, Nunes MM, Leite I, Campelo M, Leão C, Souza JdC, RF. L, Fernandes A. Chikungunya 587 virus infection with severe neurologic manifestations: report of four fatal cases. Revista da 588 Sociedade Brasileira de Medicina Tropical. 2017;50:265-8 Wielanek AC, Monredon JD, Amrani ME, Roger JC, Serveaux JP. Guillain-barré syndrome 589 37. 590 complicating a chikungunya virus infection. . Neurology. 2007;69(22):2105 591 38. Singh SS, Manimunda SP, Sugunan AP, Sahina, Vijayachari P. Four cases of acute flaccid 592 paralysis associated with chikungunya virus infection. Epidemiology and infection. 2008;136(9):1277-593 80 594 39. Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV. Increased mortality rate 595 associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis. 2008 Mar;14(3):412-5 596 40. Josseran L, Paquet C, Zehgnoun A, Caillere N, Le Tertre A, Solet J-L, Ledrans M. Chikungunya 597 disease outbreak, Reunion Island. Emerging infectious diseases. 2006;12(12):1994-5 598 Soumahoro M-K, Gérardin P, Boëlle P-Y, Perrau J, Fianu A, Pouchot J, Malvy D, Flahault A, 41. 599 Favier F, Hanslik T. Impact of Chikungunya Virus Infection on Health Status and Quality of Life: A 600 Retrospective Cohort Study. PLOS ONE. 2009;4(11):e7800 601 Ahmed R, Hassan S, Abdallah K, Enan M. Breeding and Resting Behaviour of Aedes aegypti in 42. 602 Indoor and Outdoor Environment in Kassala City, Sudan 2014/2015. Health Science Journal. 2019;13 603 (5:672)604 43. Ahmed R, Hassan S. Seasonal indices of Aedes aegypti (Diptera: Culicidae) in an urban area 605 of Kassala City, Sudan, 2014-2015. Europ Acad Res. 2019 V1(10) 606 44. Ahmed R, Hassan S, Elrahman A. Climatic Factors Affecting Density of Aedes aegypti 607 (Diptera: Culicidae) in Kassala City, Sudan 2014/2015. Asploro Journal of Biomedical and Clinical Case 608 Reports. 2019;2(2):58-68 609 45. International Severe Acute Respiratory and Emerging Infections Consortium, World Health 610 Organisation. ISARIC-WHO Clinical Characterization Protocol for Severe Emerging Infections (v.3 611 2014) [Accessed 6 October 2016]. Available from: https://isaric.tghn.org/protocols/clinical-612 characterization-protocol/.